glp-1 drug liraglutide may protect against dementia Could diabetes and weight loss drugs treat Alzheimer's disease? Older GLP-1 drug may help

That's kind of in its infancy, but that's where we're going

Three participants prematurely withdrawn reported an AE related to a gastrointestinal disorder (lipase increase, nausea, constipation), a known class effect for GLP-1 agonists

The qualifying diagnoses (HFpEF, uncontrolled hypertension, CKD, pre-diabetes, prior MI, prior stroke, PAD) are the conditions where GLP-1 trials have shown direct benefit or strong biological plausibility for benefit

The effect of GLP-1RA on the eGFR-related endpoint worsening kidney function was neutral in the main analysis (HR 0.86, 95% CI 0.721.02), while a statistically significant benefit was detected in the sensitivity analysis excluding ELIXA (HR 0.82, 95% CI 0.690.98) [11]

Customers browsing broader non-insulin diabetes medicines can use the non-insulin diabetes medications category for class-level navigation

"Tirzepatide is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist." JCI Insight, 2020, 5(17), e140532